Duloxetine: The Next Gold Standard for Treating Depression and Motor Symptoms in Parkinson's Disease?
- PMID: 40355998
- PMCID: PMC12069917
- DOI: 10.62641/aep.v53i3.1864
Duloxetine: The Next Gold Standard for Treating Depression and Motor Symptoms in Parkinson's Disease?
Abstract
No abstract present.
Conflict of interest statement
The author declares no conflict of interest.
Similar articles
-
The Effectiveness and Safety Analysis of Duloxetine in Treating Comorbid Depression in Parkinson's Disease: A Retrospective Study.Actas Esp Psiquiatr. 2024 Oct;52(5):607-615. doi: 10.62641/aep.v52i5.1634. Actas Esp Psiquiatr. 2024. PMID: 39403917 Free PMC article.
-
A double-blind, randomized controlled trial of duloxetine for pain in Parkinson's disease.J Neurol Sci. 2020 Jul 15;414:116833. doi: 10.1016/j.jns.2020.116833. Epub 2020 Apr 9. J Neurol Sci. 2020. PMID: 32299024 Clinical Trial.
-
Depression in Parkinson's disease.Pharmacol Rep. 2013;65(6):1545-57. doi: 10.1016/s1734-1140(13)71516-0. Pharmacol Rep. 2013. PMID: 24553003 Review.
-
Duloxetine, a serotonin and norepinephrine reuptake inhibitor, may be a double-edged sword for patients with advanced Parkinson's disease.Asian J Psychiatr. 2020 Apr;50:102031. doi: 10.1016/j.ajp.2020.102031. Epub 2020 Mar 28. Asian J Psychiatr. 2020. PMID: 32272360 No abstract available.
-
[Depression is common in Parkinson disease. Limited studies on symptoms and treatment].Lakartidningen. 1994 Nov 16;91(46):4270, 4275-6. Lakartidningen. 1994. PMID: 7808129 Review. Swedish. No abstract available.
References
-
- Peña E, Mata M, López-Manzanares L, Kurtis M, Eimil M, Martínez-Castrillo JC, et al. Antidepressants in Parkinson’s disease. Recommendations by the movement disorder study group of the Neurological Association of Madrid. Neurología . 2018;33:395–402. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical